# The Collaborative Collapse: Bile Acid Dysmetabolism as a Central Pathogenic Driver in Canine and Feline Multi-Systemic Disorders—From Mechanisms to Precision Therapeutics

## TL;DR

Bile acid imbalances in dogs and cats can cause multiple health issues, and understanding these patterns allows for more precise and effective treatments.

## Contribution

The paper identifies two distinct bile acid dysmetabolism profiles and proposes targeted therapeutic strategies for each.

## Key findings

- Microbial collapse leads to secondary bile acid depletion and worsens inflammatory conditions like chronic enteropathy.
- Hepato-biliary spillover causes primary bile acid excess and is linked to liver and systemic diseases.
- Precision therapies, such as SynComs and TUDCA, offer more effective treatment than traditional methods like FMT.

## Abstract

Bile acids are best known for their role in digestion, but they also act as vital chemical signals that keep an animal’s metabolism, immune system, and organs healthy. In dogs and cats, this robust balance is often disrupted in two specific ways. Sometimes, the beneficial gut bacteria that process these acids are lost due to antibiotics or illness, leading to a “microbial collapse” that is often associated with chronic diarrhea or can remain asymptomatic. In other cases, liver issues cause toxic bile acids to “spill over” into the digestive tract. Our review shows that these two problems are distinct and require very different approaches: one needs a restoration of healthy bacteria, while the other requires medication to trap and remove excess acids. By identifying these specific patterns, veterinarians can move away from trial-and-error treatments and use more targeted therapies. This shift toward precision medicine helps ensure that companion animals suffering from complex, long-term digestive and liver diseases can lead more comfortable and healthy lives.

Veterinary metabolomics has redefined bile acids (BAs) from simple digestive surfactants to systemic endocrine signals within a microbial–host metabolic axis. This review aims to evaluate how BA dysmetabolism acts as a central pathogenic factor in canine and feline disease. We analyze the BA pool’s integrity, which depends on a specialized functional guild, primarily Peptacetobacter hiranonis, responsible for 7α-dehydroxylation. We delineate two principal pathological profiles: (1) microbial collapse, characterized by secondary bile acid (SBA) depletion and compromised farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) signaling, which exacerbates inflammation in chronic enteropathy (CE), protein-losing enteropathy (PLE), and exocrine pancreatic insufficiency (EPI); and (2) hepato-biliary spillover, wherein host-induced dysfunction results in primary bile acid (PBA) excess. Recent data have linked these disruptions to skeletal health, feline renal fibrosis, cardiac remodeling in myxomatous mitral valve disease (MMVD), and neuroinflammation in epilepsy and hepatic encephalopathy. The discovery of microbially conjugated bile acids (MCBAs) and microbial extracellular vesicles (MEVs) reveals highly specific, vesicle-mediated communication pathways impacting systemic health. Diagnostic protocols should prioritize functional profiling, including the dysbiosis index (DI), serum conjugated BA analysis, and SBA/PBA ratios. Clinical management is moving beyond empirical fecal microbiota transplantation (FMT), towards precision synthetic microbial consortia (SynComs), neuroprotective BAs like tauroursodeoxycholic acid (TUDCA), and molecular postbiotics to restore the collaborative metabolome.